Royalty Pharma plc announces a fourth quarter 2026 dividend of $0.235 per share, payable December 10, 2026.
Investivoq AI Summary
Royalty Pharma plc has announced a fourth-quarter dividend of $0.235 per Class A ordinary share, set to be paid on December 10, 2026, to shareholders on record as of November 13, 2026. The company, established in 1996, is a leading purchaser of biopharmaceutical royalties and supports innovation within the industry by collaborating with various partners, from academic institutions to major pharmaceutical companies. Royalty Pharma has built a diverse portfolio of royalties, which includes more than 35 commercial products, such as Vertex's Trikafta and Biogen's Tysabri, and also supports late-stage clinical trials and product launches through direct funding arrangements. For more details, visit their website.
Potential Positives
- The board of directors has approved a dividend payment of $0.235 per Class A ordinary share, indicating financial stability and profitability.
- The dividend payment reflects the company's commitment to returning value to shareholders.
- The scheduled payment date and record date provide clear communication to shareholders, enhancing investor confidence.
- The company has a robust portfolio that includes royalties on over 35 commercial products, showcasing its strong position in the biopharmaceutical industry.
Potential Negatives
- The announcement of a dividend might indicate limited reinvestment in growth opportunities, raising concerns about the company's long-term strategy and financial health.
- The specifics of the dividend amount ($0.235) may be seen as lower than expected by some investors, potentially leading to a negative reaction in the stock market.
FAQ
When will the dividend for Q4 2026 be paid?
The dividend will be paid on December 10, 2026.
What is the amount of the dividend approved by Royalty Pharma?
The approved dividend is $0.235 per Class A ordinary share.
Who is eligible to receive the dividend?
Shareholders of record at the close of business on November 13, 2026, are eligible.
What is Royalty Pharma known for?
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the industry.
How many commercial products does Royalty Pharma's portfolio include?
Royalty Pharma's portfolio includes royalties on more than 35 commercial products.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
EARLY ACCESS
Receive RPRX Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
$RPRX Insider Trading Activity
$RPRX insiders have traded $RPRX stock on the open market 20 times in the past 6 months. Of those trades, 0 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $RPRX stock by insiders over the last 6 months:
- CHRISTOPHER HITE (EVP & Chairman, Partnering) has made 0 purchases and 9 sales selling 480,000 shares for an estimated $27,355,092.
- TERRANCE P. COYNE (EVP & CFO) has made 0 purchases and 5 sales selling 110,192 shares for an estimated $5,853,507.
- MARSHALL URIST (EVP, Research & Investments) has made 0 purchases and 5 sales selling 49,691 shares for an estimated $2,694,090.
- GREGORY NORDEN sold 3,045 shares for an estimated $161,385
To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.
$RPRX Revenue
$RPRX had revenues of $674M in Q2 2026. This is an increase of 16.47% from the same period in the prior year.
You can track RPRX financials on Investivoq's RPRX stock page.
You can access data on RPRX stock through the Investivoq API.
$RPRX Hedge Fund Activity
We have seen 375 institutional investors add shares of $RPRX stock to their portfolio, and 221 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 9,259,396 shares (+478.7%) to their portfolio in Q2 2026, for an estimated $519,174,333
- BAILLIE GIFFORD & CO removed 6,993,190 shares (-41.1%) from their portfolio in Q2 2026, for an estimated $392,108,163
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,980,633 shares (-66.6%) from their portfolio in Q2 2026, for an estimated $279,264,092
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,092,313 shares (-99.9%) from their portfolio in Q2 2026, for an estimated $173,385,989
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,083,528 shares (+inf%) to their portfolio in Q2 2026, for an estimated $172,893,414
- CAPITAL ADVISOR NETWORK LLC removed 3,030,974 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $169,946,712
- JANE STREET GROUP, LLC removed 2,346,922 shares (-97.8%) from their portfolio in Q2 2026, for an estimated $131,591,916
To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.
$RPRX Analyst Ratings
Wall Street analysts have issued reports on $RPRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 05/07/2026
To track analyst ratings and price targets for $RPRX, check out Investivoq's $RPRX forecast page.
$RPRX Price Targets
Multiple analysts have issued price targets for $RPRX recently. We have seen 3 analysts offer price targets for $RPRX in the last 6 months, with a median target of $58.0.
Here are some recent targets:
- Chris Schott from JP Morgan set a target price of $58.0 on 05/07/2026
- Geoff Meacham from Citigroup set a target price of $66.0 on 05/07/2026
- Ashwani Verma from UBS set a target price of $57.0 on 04/21/2026
Full Release
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.
The dividend will be paid on December 10, 2026, to shareholders of record at the close of business on November 13, 2026.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit
www.royaltypharma.com
.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
